Cargando…
The effect of cangrelor and access site on ischaemic and bleeding events: insights from CHAMPION PHOENIX
AIMS: To assess whether the use of the femoral or radial approach for percutaneous coronary intervention (PCI) interacted with the efficacy and safety of cangrelor, an intravenous P2Y(12) inhibitor, in CHAMPION PHOENIX. METHODS AND RESULTS: A total of 11 145 patients were randomly assigned in a doub...
Autores principales: | Gutierrez, J. Antonio, Harrington, Robert A., Blankenship, James C., Stone, Gregg W., Steg, Ph. Gabriel, Gibson, C. Michael, Hamm, Christian W., Price, Matthew J., Généreux, Philippe, Prats, Jayne, Deliargyris, Efthymios N., Mahaffey, Kenneth W., White, Harvey D., Bhatt, Deepak L., Bhatt, DL, Stone, GW, Mahaffey, KW, Gibson, CM, Steg, PG, Hamm, CW, Price, MJ, Leonardi, S, Gallup, D, Bramucci, E, Radke, PW, Widimsky, P, Tousek, F, Tauth, J, Spriggs, D, McLaurin, BT, Angiolillo, DJ, Genereux, P, Liu, T, Prats, J, Todd, M, Skerjanec, S, White, HD, Harrington, RA |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4823635/ https://www.ncbi.nlm.nih.gov/pubmed/26400827 http://dx.doi.org/10.1093/eurheartj/ehv498 |
Ejemplares similares
-
Consistent Reduction in Periprocedural Myocardial Infarction With Cangrelor as Assessed by Multiple Definitions: Findings From CHAMPION PHOENIX (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition)
por: Cavender, Matthew A., et al.
Publicado: (2016) -
Efficacy and Safety of Cangrelor in Women Versus Men During Percutaneous Coronary Intervention: Insights From the Cangrelor versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION PHOENIX) Trial
por: O’Donoghue, Michelle L., et al.
Publicado: (2016) -
Variation in Patient Profiles and Outcomes in US and Non-US Subgroups of the Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION) PHOENIX Trial
por: Vaduganathan, Muthiah, et al.
Publicado: (2016) -
Ischemic Events Occur Early in Patients Undergoing Percutaneous Coronary Intervention and Are Reduced With Cangrelor: Findings From CHAMPION PHOENIX
por: Cavender, Matthew A., et al.
Publicado: (2021) -
Impact of lesion complexity on peri-procedural adverse events and the benefit of potent intravenous platelet adenosine diphosphate receptor inhibition after percutaneous coronary intervention: core laboratory analysis from 10 854 patients from the CHAMPION PHOENIX trial
por: Stone, Gregg W, et al.
Publicado: (2018)